Academic Journal
Clinical Efficacy of 2% Rebamipide in Patients With Video Display Terminal-Associated Dry Eye Disease: A Prospective, Randomized, Double-Blinded Study.
| Title: | Clinical Efficacy of 2% Rebamipide in Patients With Video Display Terminal-Associated Dry Eye Disease: A Prospective, Randomized, Double-Blinded Study. |
|---|---|
| Authors: | Lee YW; Department of Ophthalmology (Y.W.L.), Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Republic of Korea; and Saevit Eye Hospital (S.B.H.), Goyang, Korea., Han SB |
| Source: | Eye & contact lens [Eye Contact Lens] 2024 Aug 01; Vol. 50 (8), pp. 342-347. Date of Electronic Publication: 2024 May 23. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101160941 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-233X (Electronic) Linking ISSN: 15422321 NLM ISO Abbreviation: Eye Contact Lens Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hagerstown, Md. : Lippincott Williams & Wilkins, c2003- |
| MeSH Terms: | Dry Eye Syndromes*/drug therapy , Quinolones*/administration & dosage , Quinolones*/therapeutic use , Alanine*/analogs & derivatives , Alanine*/therapeutic use , Alanine*/administration & dosage , Tears*/metabolism , Tears*/physiology , Ophthalmic Solutions* , Computer Terminals*, Hyaluronic Acid/administration & dosage ; Hyaluronic Acid/analogs & derivatives ; Humans ; Double-Blind Method ; Prospective Studies ; Male ; Female ; Middle Aged ; Adult ; Aged ; Treatment Outcome |
| Abstract: | Purpose: To compare the effects of 2% rebamipide clear solution and 0.1% sodium hyaluronate eye drops in patients with visual display terminal (VDT)-related dry eye disease (DED). Design: Prospective, randomized, double-blinded Study. Methods: This was a prospective, double-blind, and randomized controlled study. Patients with VDT-related DED were randomly allocated to a 2% rebamipide (REB) group or a 0.1% sodium hyaluronate (HYA) group (4 times/day for 4 weeks). The ocular surface disease index (OSDI), dry eye questionnaire-5 (DEQ-5), Placido disk-tear film analyzer, fluorescein-stained tear break-up time (FBUT), ocular surface staining score, and Schirmer 1 test were examined before and after the instillation of drug. Results: A total of 56 eyes of 28 patients (28 eyes of 14 patients in each group) were included. There were no significant differences in the baseline data. The OSDI, DEQ-5, FBUT, and conjunctival erosion scores improved significantly in both groups after treatment. In the REB group, corneal staining and bulbar nasal redness scores also improved significantly after treatment ( P <0.001 and 0.036, respectively), whereas no significant differences were found in these parameters in the HYA group ( P =0.326 and 0.118, respectively). The REB group showed a significantly larger decrease in the corneal staining score than the HYA group ( P =0.016). No adverse reactions were observed. Conclusions: A 2% rebamipide clear solution effectively improved the symptoms and signs in patients with VDT-related DED and was superior to 0.1% sodium hyaluronate ophthalmic solution in improving corneal epithelial damage, making it a safe and effective treatment option for VDT-related DED. (Copyright © 2024 Contact Lens Association of Ophthalmologists.) |
| Competing Interests: | The authors have no conflicts of interest to disclose. |
| References: | Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf 2017;15:438–510. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf 2017;15:802–812. Tsubota K, Yokoi N, Shimazaki J, et al. New perspectives on dry eye definition and diagnosis: A consensus report by the asia dry eye society. Ocul Surf 2017;15:65–76. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study. Cornea 2012;31:472–478. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723–728. Cai Y, Wei J, Zhou J, et al. Prevalence and incidence of dry eye disease in Asia: A systematic review and meta-analysis. Ophthalmic Res 2022;65:647–658. Li M, Zeng L, Mi S, et al. A multicenter study of the prevalence of dry eye disease in Chinese refractive surgery candidates. Ophthalmic Res 2021;64:224–229. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–365. Tandon R, Vashist P, Gupta N, et al. Association of dry eye disease and sun exposure in geographically diverse adult (≥40 years) populations of India: The SEED (sun exposure, environment and dry eye disease) study - second report of the ICMR-EYE SEE study group. Ocul Surf 2020;18:718–730. Kamøy B, Magno M, Nøland ST, et al. Video display terminal use and dry eye: Preventive measures and future perspectives. Acta Ophthalmol 2022;100:723–739. Uchino M, Uchino Y, Dogru M, et al. Dry eye disease and work productivity loss in visual display users: The Osaka study. Am J Ophthalmol 2014;157:294–300. Yokoi N, Uchino M, Uchino Y, et al. Importance of tear film instability in dry eye disease in office workers using visual display terminals: The Osaka study. Am J Ophthalmol 2015;159:748–754. Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of rebamipide in organic and functional dyspepsia: A systematic review and meta-analysis. Dig Dis Sci 2018;63:1250–1260. Arakawa T, Kobayashi K, Yoshikawa T, et al. Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998;43:5S–13S. Takeji Y, Urashima H, Aoki A, et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther 2012;28:259–263. Uchino Y, Woodward AM, Argueso P. Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells. Exp Eye Res 2016;153:1–7. Ueda K, Matsumiya W, Otsuka K, et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol 2015;15:58. Eom Y, Chung SH, Chung TY, et al. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: A multicenter randomized trial. BMC Ophthalmol 2023;23:343. Utsunomiya T, Kawahara A, Hanada K, et al. Effects of diquafosol ophthalmic solution on quality of life in dry eye assessed using the dry eye-related quality-of-life score questionnaire: Effectiveness in patients while reading and using visual display terminals. Cornea 2017;36:908–914. Titiyal JS, Falera RC, Kaur M, et al. Prevalence and risk factors of dry eye disease in North India: Ocular surface disease index-based cross-sectional hospital study. Indian J Ophthalmol 2018;66:207–211. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640–650. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf 2017;15:539–574. Fjaervoll H, Fjaervoll K, Magno M, et al. The association between visual display terminal use and dry eye: A review. Acta Ophthalmol 2022;100:357–375. Yee RW, Sperling HG, Kattek A, et al. Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf 2007;5:308–315. Hori Y. Secreted mucins on the ocular surface. Invest Ophthalmol Vis Sci 2018;59:DES151–DES156. Ohguchi T, Kojima T, Ibrahim OM, et al. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest Ophthalmol Vis Sci 2013;54:7793–7802. Kinoshita S, Awamura S, Nakamichi N, et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014;157:576–583 e1. Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: A randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;119:2471–2478. Koh S, Inoue Y, Sugmimoto T, et al. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219–1223. Igarashi A, Kamiya K, Kobashi H, et al. Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery. Cornea 2015;34:895–900. Mun Y, Kwon JW, Oh JY. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease. BMC Ophthalmol 2018;18:237. Jang DJ, Lee JH, Kim DH, et al. The development of super-saturated rebamipide eye drops for enhanced solubility, stability, patient compliance, and bioavailability. Pharmaceutics 2023;15:950. 10.3390/pharmaceutics15030950. (PMID: 10.3390/pharmaceutics15030950) Sutphin JE, Ying GS, Bunya VY, et al. Correlation of measures from the OCULUS Keratograph and clinical assessments of dry eye disease in the dry eye assessment and management study. Cornea 2022;41:845–851. Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology 2013;120:1158–1165. Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian J Ophthalmol 2023;71:1598–1602. Firat PG, Doganay S. Corneal hysteresis in patients with dry eye. Eye (Lond). 2011;25:1570–1574. Kuze M, Ayaki M, Yuki K, et al. Seasonal variation of intra-ocular pressure in glaucoma with and without dry eye. Sci Rep 2020;10:13949. |
| Grant Information: | Kukje Pharma (Gyeonggi-do, Republic of Korea). |
| Substance Nomenclature: | LR583V32ZR (rebamipide) 0 (Quinolones) 0 (Ophthalmic Solutions) OF5P57N2ZX (Alanine) 9004-61-9 (Hyaluronic Acid) |
| Entry Date(s): | Date Created: 20240523 Date Completed: 20240725 Latest Revision: 20250730 |
| Update Code: | 20260130 |
| DOI: | 10.1097/ICL.0000000000001101 |
| PMID: | 38780404 |
| Database: | MEDLINE |
| ISSN: | 1542-233X |
|---|---|
| DOI: | 10.1097/ICL.0000000000001101 |